O'CALLAGHAN BRIAN 4

4 · Bolt Biotherapeutics, Inc. · Filed Dec 16, 2025

Form 4

Period: 2025-12-12

Director

Transactions

Award
Director Stock Option (Right to Buy)
2025-12-12+1,393→ 1,393 total
Exercise: $5.44Exp: 2031-11-16→ Common Stock (1,393 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,393→ 0 total
Exercise: $180.20Exp: 2031-11-16→ Common Stock (1,393 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,810→ 1,810 total
Exercise: $5.44Exp: 2032-03-23→ Common Stock (1,810 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,810→ 0 total
Exercise: $60.60Exp: 2032-03-23→ Common Stock (1,810 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,250→ 1,250 total
Exercise: $5.44Exp: 2032-06-09→ Common Stock (1,250 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,250→ 0 total
Exercise: $39.80Exp: 2032-06-09→ Common Stock (1,250 underlying)
Award
Director Stock Option (Right to Buy)
2025-12-12+1,100→ 1,100 total
Exercise: $5.44Exp: 2034-06-11→ Common Stock (1,100 underlying)
Disposition to Issuer
Director Stock Option (Right to Buy)
2025-12-12−1,100→ 0 total
Exercise: $15.36Exp: 2034-06-11→ Common Stock (1,100 underlying)

Footnotes (8)

[F1]The option is fully vested and exercisable.
[F2]The reporting person agreed to cancellation of an option granted on November 17, 2021, in exchange for a new option having a lower exercise price.
[F3]The reporting person agreed to cancellation of an option granted on March 24, 2022, in exchange for a new option having a lower exercise price.
[F4]The reporting person agreed to cancellation of an option granted on June 10, 2022, in exchange for a new option having a lower exercise price.
[F5]The reporting person agreed to cancellation of an option granted on June 12, 2023, in exchange for a new option having a lower exercise price.
[F6]The reporting person agreed to cancellation of an option granted on June 12, 2024, in exchange for a new option having a lower exercise price.
[F7]The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
[F8]The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.

Documents

1 file